BioMarin Pharmaceuticals Inc

XNASHealth care

Last traded price · USD

$57.98

+1.49%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $57.13
Volume: 2,782
Day's high: —
Day's low: —

In brief

BioMarin Pharmaceuticals Inc is a health care company listed on Nasdaq, valued at about $11.22B.
Its shares closed at $57.13 on 4 Nov 2026, up 8.8% over the past year.
From India you can buy BMRN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy BioMarin Pharmaceuticals Inc (BMRN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole BMRN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade BMRN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $57.13 was 4.9% below its 50-day average ($60.06) and 2.3% below its 200-day average ($58.46). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: +1.6% (SPY −1.6%, XLV +13.5%). 3 months: −4.6% (SPY −0.4%, XLV +15.5%). 1 year: +8.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BMRN, SPY and XLV · as of 4 Nov 2026
36% of the way up its 52-week range
Closed at $57.13 on 4 Nov 2026: 19.5% below the 52-week high of $70.98 (12 Aug 2026) and 16.0% above the low of $49.26 (18 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 6.2% of shares outstanding
12.1M shares were sold short at the 15 Oct 2026 settlement, 6.2% of the 193.6M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.6%

6 months+4.6%

1 year+8.8%

5 years−31.5%

Newswire

About

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Website

Notable moves

December 19, 2025
+17.71%
September 16, 2024
−17.71%
November 7, 2023
+12.16%

BioMarin Pharmaceuticals Inc

XNASHealth care

Last traded price · USD

$57.98

+1.49%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $57.13
Volume: 2,782
Day's high: —
Day's low: —

In brief

BioMarin Pharmaceuticals Inc is a health care company listed on Nasdaq, valued at about $11.22B.
Its shares closed at $57.13 on 4 Nov 2026, up 8.8% over the past year.
From India you can buy BMRN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy BioMarin Pharmaceuticals Inc (BMRN) shares from India?

Do I need the price of a whole BMRN share to invest?

How much can I invest in US stocks in a year?

Can I trade BMRN options or futures?

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $57.13 was 4.9% below its 50-day average ($60.06) and 2.3% below its 200-day average ($58.46). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: +1.6% (SPY −1.6%, XLV +13.5%). 3 months: −4.6% (SPY −0.4%, XLV +15.5%). 1 year: +8.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BMRN, SPY and XLV · as of 4 Nov 2026
36% of the way up its 52-week range
Closed at $57.13 on 4 Nov 2026: 19.5% below the 52-week high of $70.98 (12 Aug 2026) and 16.0% above the low of $49.26 (18 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 6.2% of shares outstanding
12.1M shares were sold short at the 15 Oct 2026 settlement, 6.2% of the 193.6M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.6%

6 months+4.6%

1 year+8.8%

5 years−31.5%

Newswire

About

Website

Notable moves

December 19, 2025
+17.71%
September 16, 2024
−17.71%
November 7, 2023
+12.16%

BioMarin Pharmaceuticals Inc

BioMarin Pharmaceuticals Inc in brief

Below its 50- and 200-day averages

Behind SPY and its sector fund XLV over 1 year

36% of the way up its 52-week range

Short interest at 6.2% of shares outstanding

BioMarin Pharmaceuticals Inc

BioMarin Pharmaceuticals Inc in brief

Below its 50- and 200-day averages

Behind SPY and its sector fund XLV over 1 year

36% of the way up its 52-week range

Short interest at 6.2% of shares outstanding